• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

1例肝细胞-胆管细胞癌合并症的诊断与治疗及文献复习

A Case of Combined Hepatocellular-Cholangiocarcinoma Diagnosis and Treatment With Literature Review.

作者信息

Chen Xuliang, Zhu Hengkai, Tao Liyan, Zheng Shusen, Guo Hua

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College Zhejiang Shuren University Hangzhou P. R. China.

出版信息

Clin Case Rep. 2025 Aug 13;13(8):e70652. doi: 10.1002/ccr3.70652. eCollection 2025 Aug.

DOI:10.1002/ccr3.70652
PMID:40809514
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12344444/
Abstract

This report presents a rare case of a 43-year-old man with unresectable combined hepatocellular-cholangiocarcinoma who, after undergoing transarterial chemoembolization, systemic chemotherapy, and stereotactic body radiation therapy, accepted curative resection and obtained an overall survival of 25 months to date. The case highlights the need for adaptable treatment regimens due to the tumor's components and underscores the importance of surgery for long-term success.

摘要

本报告介绍了一例罕见病例，一名43岁男性患有不可切除的肝细胞胆管癌，在接受经动脉化疗栓塞、全身化疗和立体定向体部放射治疗后，接受了根治性切除，迄今为止总生存期为25个月。该病例凸显了由于肿瘤成分而需要采用适应性治疗方案的必要性，并强调了手术对于长期成功的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/40f688555088/CCR3-13-e70652-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/caa1126e08e7/CCR3-13-e70652-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/e8d2e21d8752/CCR3-13-e70652-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/56a31abef00b/CCR3-13-e70652-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/c8b0063d71a1/CCR3-13-e70652-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/ed8e209e7323/CCR3-13-e70652-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/40f688555088/CCR3-13-e70652-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/caa1126e08e7/CCR3-13-e70652-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/e8d2e21d8752/CCR3-13-e70652-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/56a31abef00b/CCR3-13-e70652-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/c8b0063d71a1/CCR3-13-e70652-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/ed8e209e7323/CCR3-13-e70652-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a76e/12344444/40f688555088/CCR3-13-e70652-g004.jpg

相似文献

1
A Case of Combined Hepatocellular-Cholangiocarcinoma Diagnosis and Treatment With Literature Review.1例肝细胞-胆管细胞癌合并症的诊断与治疗及文献复习
Clin Case Rep. 2025 Aug 13;13(8):e70652. doi: 10.1002/ccr3.70652. eCollection 2025 Aug.
2
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases.经动脉（化疗）栓塞与全身化疗治疗结直肠癌肝转移。
Cochrane Database Syst Rev. 2024 Aug 9;8(8):CD012757. doi: 10.1002/14651858.CD012757.pub2.
3
External beam radiotherapy for unresectable hepatocellular carcinoma.不可切除肝细胞癌的外照射放疗
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
4
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.可切除胆管癌的术后辅助化疗。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.
5
STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study.STRONG II试验：不可切除的肝门部胆管癌化疗后立体定向体部放射治疗——一项单臂多中心II期研究。
BMJ Open. 2025 Jul 16;15(7):e097545. doi: 10.1136/bmjopen-2024-097545.
6
Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.不同经动脉栓塞疗法单独或联合局部消融或辅助全身治疗对不可切除肝细胞癌的比较疗效：一项随机对照试验的网状Meta分析
PLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.0184597. eCollection 2017.
7
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.神经外科医生大会关于化疗在成人新诊断的世界卫生组织二级弥漫性胶质瘤中作用的系统评价和循证指南：更新版
J Neurooncol. 2025 Jan;171(2):279-298. doi: 10.1007/s11060-024-04861-6. Epub 2024 Nov 20.
8
An aggressive, unresected pineoblastoma in an adult woman: the role of exclusive radiotherapy - a case report and literature review.一名成年女性的侵袭性、未切除松果体母细胞瘤：单纯放疗的作用——病例报告及文献综述
Ecancermedicalscience. 2025 May 15;19:1909. doi: 10.3332/ecancer.2025.1909. eCollection 2025.
9
Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices.肝细胞胆管细胞癌碰撞瘤：当前治疗实践的更新。
Am Surg. 2023 Jun;89(6):2685-2692. doi: 10.1177/00031348221124323. Epub 2022 Aug 27.
10
Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis.不可切除性肝内胆管癌患者的传统与载药微球经动脉化疗栓塞术：一项系统评价与汇总分析
J Cancer Res Clin Oncol. 2023 Jan;149(1):531-540. doi: 10.1007/s00432-022-04485-1. Epub 2022 Nov 19.

本文引用的文献

1
Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.基于人群队列的 HCC/CCA 混合癌的临床特征。
J Gastrointestin Liver Dis. 2023 Jun 22;32(2):190-196. doi: 10.15403/jgld-4893.
2
Hepatocellular Carcinoma: New Developments.肝细胞癌：新进展。
Clin Liver Dis. 2023 Feb;27(1):85-102. doi: 10.1016/j.cld.2022.08.004. Epub 2022 Oct 18.
3
Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.肝细胞-胆管细胞癌：多学科团队应了解的内容。
Diagnostics (Basel). 2022 Apr 2;12(4):890. doi: 10.3390/diagnostics12040890.
4
Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.联合肝细胞癌-胆管细胞癌和肝内胆管细胞癌与肝细胞癌局部区域治疗的疗效评价：倾向评分匹配研究。
Clin Radiol. 2022 Feb;77(2):121-129. doi: 10.1016/j.crad.2021.10.013. Epub 2021 Nov 14.
5
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit.多中心英国审计：晚期肝细胞癌的活检结果。
Br J Cancer. 2021 Nov;125(10):1350-1355. doi: 10.1038/s41416-021-01535-2. Epub 2021 Sep 15.
6
A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.肝细胞-胆管细胞癌联合诊断与治疗的现代方法
Curr Hepatol Rep. 2020 Dec;19(4):478-485. doi: 10.1007/s11901-020-00556-4. Epub 2020 Oct 31.
7
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.肝细胞癌合并胆管细胞癌、肝细胞癌和肝内胆管细胞癌术后的临床特征和预后因素：倾向评分匹配分析。
Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021.
8
Epidemiology of Hepatocellular Carcinoma.肝细胞癌的流行病学
Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24.
9
Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.局部区域治疗肝内胆管细胞癌与肝细胞癌的疗效比较：一项倾向评分匹配研究。
J Vasc Interv Radiol. 2019 Sep;30(9):1317-1324. doi: 10.1016/j.jvir.2019.03.024. Epub 2019 Jul 30.
10
Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.联合型肝细胞癌-胆管细胞癌的基因组分析揭示其与肝细胞癌具有相似的遗传学特征。
J Pathol. 2019 Jun;248(2):164-178. doi: 10.1002/path.5243. Epub 2019 Mar 8.